SCHEMBL7762097

SCHEMBL7762097

C[C@@H](N)C(=O)N[C@H](CCC(=O)O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 8/20 0.60
NAALAD2 Q9Y3Q0 3/20 0.60
RIMKLA Q8IXN7 1/20 0.60
NOD1 Q9Y239 1/20 0.57
GABRP O00591 2/20 0.50
GABRD O14764 2/20 0.50
GABRA1 P14867 2/20 0.50
GABRB1 P18505 2/20 0.50
GABRG2 P18507 2/20 0.50
GABRB3 P28472 2/20 0.50
GABRA5 P31644 2/20 0.50
GABRA3 P34903 2/20 0.50
GABRA2 P47869 2/20 0.50
GABRB2 P47870 2/20 0.50
GABRA4 P48169 2/20 0.50
GABRE P78334 2/20 0.50
GABRA6 Q16445 2/20 0.50
GABRG1 Q8N1C3 2/20 0.50
GABRG3 Q99928 2/20 0.50
GABRQ Q9UN88 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11188341 1.00 FOLH1 (0.60) FOLH1NAALAD2RIMKLANOD1GABRP
SCHEMBL7937311 1.00 FOLH1 (0.60) FOLH1NAALAD2RIMKLANOD1GABRP
SCHEMBL29959406 1.00 FOLH1 (0.60) FOLH1NAALAD2RIMKLANOD1GABRP
SCHEMBL2490631 1.00 FOLH1 (0.60) FOLH1NAALAD2RIMKLANOD1GABRP
SCHEMBL1270356 1.00 FOLH1 (0.60) FOLH1NAALAD2RIMKLANOD1GABRP
SCHEMBL23044064 1.00 FOLH1 (0.60) FOLH1NAALAD2RIMKLANOD1GABRP
Hydrochloric Acid SCHEMBL8728073 0.98 FOLH1 (0.58) FOLH1NAALAD2RIMKLANOD1GABRP
Hydrochloric Acid SCHEMBL11283847 0.98 FOLH1 (0.58) FOLH1NAALAD2RIMKLANOD1GABRP
Hydrochloric Acid SCHEMBL8728071 0.98 FOLH1 (0.58) FOLH1NAALAD2RIMKLANOD1GABRP
SCHEMBL28727840 0.96 FOLH1 (0.56) FOLH1NAALAD2RIMKLANOD1GABRP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250242064-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME ALPHA-9 ONCOLOGY INC. (CA) 2025-07-31 US claimed
EP-4511384-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME Provincial Health Services Authority (CA) 2025-02-26 EP claimed
WO-2023201435-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2023-10-26 WO claimed
US-12616761-B2 CXCR4-targeting compounds THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2026-05-05 US disclosed
US-20250242064-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME ALPHA-9 ONCOLOGY INC. (CA) 2025-07-31 US disclosed
CN-110312533-B Prodrugs of cytotoxic active agents having enzymatically cleavable groups 拜耳公司 2023-11-03 CN disclosed
CN-116457028-A Novel CXCR4 targeting compounds 省卫生服务机构 2023-07-18 CN disclosed
CN-116327974-A Antibody-drug-conjugates (ADCs) with enzymatically cleavable groups 拜耳制药股份公司 2023-06-27 CN disclosed
CN-110312533-A Prodrugs of cytotoxic active agents having an enzymatically cleavable group 拜耳公司 2019-10-08 CN disclosed
CN-107921146-A Spindle drives the antibody drug conjugate (ADC) of albumen (KSP) inhibitor and the antibody of anti-CD123 拜耳医药股份有限公司 2018-04-17 CN disclosed
WO-2001070937-A1 A NEW THERMOSTABLE D-STEREOSPECIFIC DIPEPTIDASE FROM BREVIBACILLUS BOSTELENSIS BCS-1 AND ITS USE AS A BIOCATALYST FOR THE SYNTHESIS OF PEPTIDES CONTAINING D-AMINO ACIDS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2001-09-27 WO disclosed
US-4421765-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1983-12-20 US disclosed
US-4420490-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1983-12-13 US disclosed
US-4346105-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1982-08-24 US disclosed
US-4346104-A ANTIINFLAMMATORY CIBA-GEIGY CORPORATION (US) 1982-08-24 US disclosed
US-4322436-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1982-03-30 US disclosed
US-4250192-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1981-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242064-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME CXCR4, CXCL12, ACKR3 FOLH1 497/4885NAALAD2 2878/4885RIMKLA 3283/4885
US-12616761-B2 CXCR4-targeting compounds CXCR4, CXCR2, CXCR3 FOLH1 756/4885NAALAD2 1266/4885RIMKLA 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.